Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
NL0011832936
Tue, 04.10.2022       Cosmo Pharmaceuticals N.V.
NL0011832936

Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland & Heppenheim, Germany – 04 October 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and InfectoPharm today announced the signing of a License and Distribution Agreement for Winlevi® (clascoterone) cream 1% in Germany, Italy and Austria.  Under the terms of the agreem [ … ]
Technical analysis
To the publication
Tue, 04.10.2022       Cosmo Pharmaceuticals N.V.
NL0011832936

Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland & Heppenheim, Germany – 04 October 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and InfectoPharm today announced the signing of a License and Distribution Agreement for Winlevi® (clascoterone) cream 1% in Germany, Italy and Austria.  Under the terms of the agreem [ … ]
Technical analysis
To the publication
Thu, 28.07.2022       Cosmo Pharmaceuticals N.V.
NL0011832936

Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland – 28 July 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced strong financial half-year 2022 results, with record revenue of €41.5 million up 46.1% (H1 2021: €28.4 million), EBITDA of €14.9 million up 338.2% (H1 2021: €3.4 million), operating profit of €8.1  [ … ]
Technical analysis
To the publication
Thu, 28.07.2022       Cosmo Pharmaceuticals N.V.
NL0011832936

Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland – 28 July 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced strong financial half-year 2022 results, with record revenue of €41.5 million up 46.1% (H1 2021: €28.4 million), EBITDA of €14.9 million up 338.2% (H1 2021: €3.4 million), operating profit of €8.1  [ … ]
Technical analysis
To the publication
Thu, 28.07.2022       Cosmo Pharmaceuticals N.V.
NL0011832936

Ad hoc announcement pursuant to Art. 53 LR   Dublin, Ireland & Shenyang, China – 28 July 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and 3SBio (1530.HK) today announced the signing of a License Agreement for Winlevi® (clascoterone) cream 1% in Mainland China, Taiwan, Hong Kong and Macao (“Greater China”).   Winlevi®  [ … ]
Technical analysis
To the publication
Thu, 28.07.2022       Cosmo Pharmaceuticals N.V.
NL0011832936

Ad hoc announcement pursuant to Art. 53 LR   Dublin, Ireland & Shenyang, China – 28 July 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and 3SBio (1530.HK) today announced the signing of a License Agreement for Winlevi® (clascoterone) cream 1% in Mainland China, Taiwan, Hong Kong and Macao (“Greater China”).   Winlevi®  [ … ]
Technical analysis
To the publication
Tue, 26.07.2022       Cosmo Pharmaceuticals N.V.
NL0011832936

Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland and Mumbai, India – 26 July 2022: Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies) and Cassiopea, a subsidiary of Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43 [ … ]
Technical analysis
To the publication
Tue, 26.07.2022       Cosmo Pharmaceuticals N.V.
NL0011832936

Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland and Mumbai, India – 26 July 2022: Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies) and Cassiopea, a subsidiary of Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43 [ … ]
Technical analysis
To the publication
Wed, 06.07.2022       Cosmo Pharmaceuticals N.V.
NL0011832936

Cosmo Pharmaceuticals N.V. / Key word(s): Conference Invitation to Cosmo’s Half-Year 2022 Results Webcast on 28 July 2022 06.07.2022 / 06:00 Dublin, Ireland – 6 July 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that it will publish its Half-Year 2022 results on Thursday, 28 July 2022 at 07:0 [ … ]
Technical analysis
To the publication
Wed, 06.07.2022       Cosmo Pharmaceuticals N.V.
NL0011832936

Cosmo Pharmaceuticals N.V. / Key word(s): Conference Invitation to Cosmo’s Half-Year 2022 Results Webcast on 28 July 2022 06.07.2022 / 06:00 Dublin, Ireland – 6 July 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that it will publish its Half-Year 2022 results on Thursday, 28 July 2022 at 07:0 [ … ]
Technical analysis
To the publication

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

Legend/Explanation
The newswire feed is updated several times a day. To make sure you don't miss any news, please check back here often. If you are curious about a headline or want to find out more about a publication, click on it to go to the preview and click again to go to the full news item.
Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Sunday, 06.10.2024, Calendar Week 40, 280th day of the year, 86 days remaining until EoY.